Plasmodium falciparum clearance rates in response to artesunate in Malian children with malaria: effect of acquired immunity

J Infect Dis. 2013 Jun 1;207(11):1655-63. doi: 10.1093/infdis/jit082. Epub 2013 Feb 28.

Abstract

Background: Artemisinin resistance, a long parasite clearance half-life in response to artemisinin, has been described in patients with Plasmodium falciparum malaria in southeast Asia. Few baseline half-lives have been reported from Africa, where artemisinins were recently introduced.

Methods: We treated P. falciparum malaria in 215 Malian children aged 0.5-15 years with artesunate (0, 24, 48 hours) and amodiaquine (72, 96, 120 hours). We estimated half-life by measuring parasite density every 6 hours until undetectable and evaluated the effects of age, sex, ethnicity, and red blood cell (RBC) polymorphisms on half-life. We quantified the proportion of parasitized RBCs recognized by autologous immunoglobulin G (IgG).

Results: The geometric mean half-life was 1.9 hours (95% confidence interval, 1.8-2.0) and did not correlate with parasite ex vivo susceptibility to artemisinins. In a linear model accounting for host factors, half-life decreased by 4.1 minutes for every 1-year increase in age. The proportion of parasitized RBCs recognized by IgG correlated inversely with half-life (r = -0.475; P = .0006).

Conclusions: Parasite clearance in response to artesunate is faster in Mali than in southeast Asia. IgG responses to parasitized RBCs shorten half-life and may influence this parameter in areas where age is not an adequate surrogate of immunity and correlates of parasite-clearing immunity have not been identified.

Clinical trials registration: NCT00669084.

Publication types

  • Research Support, N.I.H., Intramural

MeSH terms

  • Adaptive Immunity*
  • Adolescent
  • Amodiaquine / administration & dosage
  • Antibodies, Protozoan / blood
  • Antimalarials / administration & dosage*
  • Artemisinins / administration & dosage*
  • Artesunate
  • Child
  • Child, Preschool
  • Cohort Studies
  • Erythrocytes / parasitology
  • Female
  • Humans
  • Immunoglobulin G / blood
  • Infant
  • Malaria, Falciparum / drug therapy*
  • Malaria, Falciparum / immunology*
  • Male
  • Mali
  • Parasite Load*
  • Parasitemia / drug therapy
  • Parasitemia / immunology
  • Plasmodium falciparum / immunology*
  • Plasmodium falciparum / isolation & purification

Substances

  • Antibodies, Protozoan
  • Antimalarials
  • Artemisinins
  • Immunoglobulin G
  • Amodiaquine
  • Artesunate

Associated data

  • ClinicalTrials.gov/NCT00669084